Novo Nordisk Injectable Drugs Plant Gets FDA Warning Letter

A Novo Nordisk plant in Denmark has received a warning letter from U.S. drug inspectors, which indicates that injectable drugs manufactured at the facility may be at risk of contamination. 

The FDA warning letter was released this week, highlighting serious quality control concerns at the plant that could lead to contaminated drugs. The FDA also warned that Novo Nordisk had failed to properly investigate whether a failed batch of an unidentified drug had been distributed to the public.

At the Novo Nordisk plant, the FDA noted that a batch of an unidentified drug was found to contain too many impurities. The company responded by saying it was due to residue from one drug adhering to equipment that was also used by another. However, the FDA said the company did not launch an investigation until the problem was brought to Novo Nordisk’s attention by an FDA inspector.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

The letter also included concerns that the company’s workers failed to collect about 846 environmental monitoring (EM) samples that are a crucial part of making sure that sterile drugs are actually sterile and not being contaminated. The failures occurred between March 2010 and February 2012.

“The substantial number of missed samples suggests a pattern that raises concerns regarding your environmental program,” the warning letter states. “Collecting scheduled EM samples is a critical aspect of any environmental control program at an aseptic manufacturing facility.”

The letter also cites the company for goggles worn by workers operating inside the sterile area of the plant that are not sterilized, but only sanitized. It also complained that the goggles have openings in them which could threaten the sterility of the area.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week
Hair Relaxer Lawsuit Status Conference To Be Held With MDL Judge This Week (Posted today)

U.S. District Judge presiding over all federal hair relaxer lawsuits will meet with lawyers involved in the litigation on Thursday, to discuss the status of the claims and when to move forward with bellwether cases.

Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025
Lawyers Propose MDL Trial Dates for Baby Formula NEC Lawsuit Starting in May 2025 (Posted yesterday)

A series of four bellwether claims in the baby formula NEC lawsuit MDL will be ready to go before a federal juries in May 2025, August 2025, November 2025 and February 2026 according to a proposed trial schedule agreed upon by both plaintiffs and defendants.